论文部分内容阅读
[目的]探讨结肠癌组织ERCC1密码子118基因多态性与奥沙利铂药敏的关系。[方法]对53例结肠癌患者新鲜标本进行体外肿瘤细胞原代培养,ATP-TCA法检测肿瘤细胞对奥沙利铂的敏感性,PCR法检测肿瘤的ERCC1密码子118基因多态性,分析ERCC1密码子118基因多态性与奥沙利铂敏感性的关系。[结果]奥沙利铂总有效率为34.7%(17/49)。C/C基因组19例,有效10例,无效9例,有效率52.6%;C/T+T/T基因组30例,有效7例,无效23例,有效率23.3%。ERCC1不同基因型组间对奥沙利铂敏感性存在显著性差异(P<0.05)。[结论]ERCC1基因多态性与奥沙利铂化疗敏感性相关,ERCC1基因型检测可能有助于预测结肠癌组织对奥沙利铂化疗敏感性。
[Objective] To investigate the relationship between ERCC1 codon 118 gene polymorphism and oxaliplatin susceptibility in colon cancer. [Method] The primary cultured tumor cells of 53 fresh colon cancer patients were assayed. The sensitivity of tumor cells to oxaliplatin was detected by ATP-TCA method. The polymorphism of ERCC1 codon 118 gene was detected by PCR. Relationship between ERCC1 codon 118 gene polymorphism and oxaliplatin sensitivity. [Results] The total effective rate of oxaliplatin was 34.7% (17/49). In C / C genome, 19 cases were effective, 10 cases were effective and 9 cases were ineffective. The effective rate was 52.6%. There were 30 cases of C / T + T / T genome, 7 cases were effective, 23 cases were ineffective and the effective rate was 23.3%. There was a significant difference in the sensitivity of oxaliplatin between different genotypes of ERCC1 (P <0.05). [Conclusion] The polymorphism of ERCC1 gene is associated with the chemosensitivity of oxaliplatin. The detection of ERCC1 genotype may be helpful to predict the chemosensitivity to oxaliplatin in colon cancer tissues.